34 related articles for article (PubMed ID: 19341717)
21. An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients.
Zhen Y; Thomas-Schoemann A; Sakji L; Boudou-Rouquette P; Dupin N; Mortier L; Vidal M; Goldwasser F; Blanchet B
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Jun; 928():93-7. PubMed ID: 23602929
[TBL] [Abstract][Full Text] [Related]
22. Simultaneous determination of sunitinib and its two metabolites in plasma of Chinese patients with metastatic renal cell carcinoma by liquid chromatography-tandem mass spectrometry.
Qiu F; Bian W; Li J; Ge Z
Biomed Chromatogr; 2013 May; 27(5):615-21. PubMed ID: 23108983
[TBL] [Abstract][Full Text] [Related]
23. A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma.
Faivre L; Gomo C; Mir O; Taieb F; Schoemann-Thomas A; Ropert S; Vidal M; Dusser D; Dauphin A; Goldwasser F; Blanchet B
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Aug; 879(23):2345-50. PubMed ID: 21737360
[TBL] [Abstract][Full Text] [Related]
24. Quantitation of unbound sunitinib and its metabolite N-desethyl sunitinib (SU12662) in human plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study.
Rais R; Zhao M; He P; Xu L; Deeken JF; Rudek MA
Biomed Chromatogr; 2012 Nov; 26(11):1315-24. PubMed ID: 22259028
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
[TBL] [Abstract][Full Text] [Related]
26. Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma.
Blanchet B; Saboureau C; Benichou AS; Billemont B; Taieb F; Ropert S; Dauphin A; Goldwasser F; Tod M
Clin Chim Acta; 2009 Jun; 404(2):134-9. PubMed ID: 19341717
[TBL] [Abstract][Full Text] [Related]
27. Routine therapeutic drug monitoring of tyrosine kinase inhibitors by HPLC-UV or LC-MS/MS methods.
Miura M; Takahashi N
Drug Metab Pharmacokinet; 2016 Feb; 31(1):12-20. PubMed ID: 26732608
[TBL] [Abstract][Full Text] [Related]
28. Towards point of care systems for the therapeutic drug monitoring of imatinib.
Pearce CM; Resmini M
Anal Bioanal Chem; 2020 Sep; 412(24):5925-5933. PubMed ID: 32166445
[TBL] [Abstract][Full Text] [Related]
29. Sunitinib malate.
Kassem MG; Motiur Rahman AF; Korashy HM
Profiles Drug Subst Excip Relat Methodol; 2012; 37():363-88. PubMed ID: 22469323
[No Abstract] [Full Text] [Related]
30.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
31.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
32.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
